EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response

Yang Liu, Bohan Li, Xiujing Zheng, Decai Xiong iD, Xinshan Ye

Molecules · 17.02.2023 · 28 (4) · 1934

DOI: 10.3390/molecules28041934 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 17.02.2023. Verfasst von Yang Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Xue Yuan Rd. No. 38, Beijing 100191, Chin…. Hauptthemen laut MEDLINE: Cancer Vaccines, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, the National Key Research and Development Program of China, the Fundamental Research Funds for the Central Universities and the Open Projects Fund of NMPA Key…, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KH-1 is a tumor-associated carbohydrate antigen (TACA), which serves as a valuable target of antitumor vaccines for cancer immunotherapies. However, most TACAs are thymus-independent antigens (TD-Ag), and they tend to induce immunological tolerance, leading to their low immunogenicity. To overcome these problems, some fluorinated derivatives of the KH-1 antigen were designed, synthesized, and conjugated to the carrier protein CRM197 to form glycoconjugates, which were used for immunological studies with Freund’s adjuvant. The results showed that fluorine-modified N-acyl KH-1 conjugates can induce higher titers of antibodies, especially IgG, which can recognize KH-1-positive cancer cells and can eliminate cancer cells through complement-dependent cytotoxicity (CDC). The trifluoro-modified KH-1-TF-CRM197 showed great potential as an anticancer vaccine candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesNeoplasmsHumansFluorineImmunityImmunotherapy

Stichwörter der Autor:innen

KH-1fluoro-modificationtumor vaccinetumor-associated carbohydrate antigens

Substanzen

Cancer VaccinesFluorine

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Xue Yuan Rd. No. 38, Beijing 100191, China.
  • The NMPA Key Laboratory for Quality Research and Evaluation of Carbohydrate-Based Medicine, Shandong University, 27 Shanda Nanlu, Jinan 250100, China.

ORCID-Profile: Decai Xiong

Förderung

  • National Natural Science Foundation of China
  • the National Key Research and Development Program of China, the Fundamental Research Funds for the Central Universities and the Open Projects Fund of NMPA Key…
  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities

Zitieren

APA

Liu, Y., Li, B., Zheng, X., Xiong, D., & Ye, X. (2023). Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response. Molecules, 28(4), 1934. https://doi.org/10.3390/molecules28041934

Vancouver

Liu Y, Li B, Zheng X, Xiong D, Ye X. Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response. Molecules. 2023;28(4):1934. doi:10.3390/molecules28041934

BibTeX
@article{Liu2023,
  author = {Liu, Yang and Li, Bohan and Zheng, Xiujing and Xiong, Decai and Ye, Xinshan},
  title = {Cancer Vaccines Based on Fluorine-Modified KH-1 Elicit Robust Immune Response},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {4},
  pages = {1934},
  doi = {10.3390/molecules28041934}
}
Kostenlos starten →